PropThink: Puma's Quarterly Reveals Catalysts Around the Corner

By Jake King

Puma Biotechnology PBYI made waves last month when it uplisted to the NYSE and initiated a substantial capital raise, increasing cash and equivalents to approximately $162 million, and on Wednesday, Puma reported its 3Q financial results. More importantly, however, Puma updated investors on forthcoming development advances for its cancer drug PB272 (neratinib). Besides reporting a net loss in the third quarter of $25.9 million ($1.29 per share) and $52.4 million in the first nine months of 2012, Puma guided for the commencement of four new neratinib trials in the next year and the completion of three late-stage studies. Based on details from the report (below) the company will have a busy twelve months preparing for - and reporting on - pipeline advances; it should be a telling time for neratinib and Puma. Continue reading by clicking here. 

Read the full article at PropThink.com.

About PropThink

PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued. We offer daily market coverage, weekly feature stories, and a newsletter to investors who subscribe on PropThink.com. To learn more, follow us on Twitter or visit us at http://www.propthink.com.

Disclaimer:

You should assume that as of the publication date of any report or letter, PropThink, LLC and persons or entities with whom it has relation ships (collectively referred to as "PropThink") has a position in all stocks (and/or options of the stock) covered herein that is consistent with the position set forth in our research report. Following publication of any report or letter, PropThink intends to continue transacting in the securities covered herein, and we may be long, short, or neutral at any time hereafter regardless of our initial recommendation. To the best of our knowledge and belief, all information contained herein is accurate and reliable, and has been obtained from public sources we believe to be accurate and reliable, and not from company insiders or persons who have a relationship with company insiders. PropThink was not compensated to publish this article. Our full disclaimer is available at http://www.propthink.com/disclaimer.